Subcategory & Sub-subcategory
Specifications
- Expression System: Developed from an optimized, DMF-filed mammalian cell line delivering consistently high titer productivity for biosimilar manufacturing
- Application: Anti-TSLP monoclonal antibody biosimilar candidate targeting severe asthma and related immune/respiratory indications
- Regulatory Status: Analytical comparability demonstrated to the reference product (tezepelumab, originally approved in the United States on 2021-12-17), supporting regulatory and clinical acceptance
- Certification Standard: DMF filing in place for the production cell line, supporting global regulatory readiness and streamlined submissions
Leave your rating & comment